Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
Subscribe To Our Newsletter & Stay Updated
